SPHERTEST test to predict immunotherapy response for advanced bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a lab test (SPHERTEST) can predict how well patients with advanced bladder or urinary tract cancer respond to immunotherapy treatments. If you are starting immunotherapy for this cancer, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic urothelial cancer (a type of bladder or urinary tract cancer that has spread).
- Your doctor plans to treat you with an immunotherapy drug (a checkpoint inhibitor like Keytruda or Opdivo).
- You have not had a checkpoint inhibitor within the past year.
- You are not pregnant or breastfeeding.
- You have health insurance (or are eligible for it).
- You are not currently participating in another interventional drug study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
This trial tests a new drug called sEphB4-HSA for people with a specific type of bladder cancer (urothelial carcinoma) that has high levels of a protein called EphrinB2. The study aims to see if this drug can shrink tumors or prevent them from growing, and it compares it to standard treatments like chemotherapy or immunotherapy.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This trial is testing a simple blood test to see if it can predict how well immunotherapy will work for people with advanced cancer. It's for those newly diagnosed with certain cancers and about to start immunotherapy as their first treatment.
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Hear when a new Urogenital Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.